**SmartPA Criteria Proposal**

**Drug/Drug Class:** Antiandrogenic Agents PDL Edit  
**First Implementation Date:** April 2, 2020  
**Revised Date:** N/A  
**Prepared For:** MO HealthNet  
**Prepared By:** MO HealthNet/Conduent  
**Criteria Status:** ☒ New Criteria

### Executive Summary

**Purpose:** The MO HealthNet Pharmacy Program will implement a state-specific preferred drug list.

**Why Issue Selected:** Antiandrogenic agents inhibit the action of androgens on tumor growth in prostatic tissue. Most drugs in this class work by interfering with androgen receptor activation, androgen receptor signaling or androgen biosynthesis. Most are indicated for use in metastatic prostate cancer, aside from additional indications of nonmetastatic castration resistant prostate cancer in Nubeqa® (darolutamide) and Xtandi® (enzalutamide). All 2nd generation antiandrogenic agents should be given with gonadotropin-releasing hormone analog, aside from Erleada™, which should be given concurrently with androgen deprivation therapy. Dosage adjustment are required for Xtandi in patients taking concomitant strong CYP2C8 inhibitors or concomitant strong CYP3A4 inducers. Due to the mechanism of action for this class of drugs, patients may experience similar symptoms as those with androgen deficiency, including gynecomastia, and may increase risk for heart disease.

Total program savings for the PDL classes will be regularly reviewed.

### Program-Specific Information:

<table>
<thead>
<tr>
<th>Preferred Agents</th>
<th>Non-Preferred Agents</th>
</tr>
</thead>
<tbody>
<tr>
<td>Abiraterone</td>
<td>Erleada™</td>
</tr>
<tr>
<td>Xtandi®</td>
<td>Nubeqa®</td>
</tr>
<tr>
<td>Zytiga® 500mg</td>
<td>Yonsa®</td>
</tr>
<tr>
<td></td>
<td>Zytiga® 250mg</td>
</tr>
</tbody>
</table>

**Type of Criteria:** ☒ Increased risk of ADE  
**Data Sources:** ☒ Only Administrative Databases  
**Setting & Population**

- Drug class for review: Antiandrogenic Agents  
- Age range: All appropriate MO HealthNet participants
Approval Criteria

- Failure to achieve desired therapeutic outcomes with trial of preferred agents:
  - For Yonsa: therapeutic trial of abiraterone and Xtandi (trial defined as 1 claim in last 12 months) OR
  - For Nubeqa and Erleada: therapeutic trial of Xtandi (trial defined as 1 claim in last 12 months) OR
  - For Zytiga 250mg: Clinical Consultant review required for approval OR
  - Documented ADE/ADR to preferred agents OR
- Documented compliance on a current non-preferred therapy regimen (defined as 90/120 days)

Denial Criteria

- Lack of adequate trial on required preferred agents
- Therapy will be denied if no approval criteria are met

Required Documentation

<table>
<thead>
<tr>
<th>Laboratory Results:</th>
<th>Progress Notes:</th>
</tr>
</thead>
<tbody>
<tr>
<td>MedWatch Form:</td>
<td>Other:</td>
</tr>
</tbody>
</table>

Disposition of Edit

Denial: Exception Code “0160” (Preferred Drug List)
Rule Type: PDL

Default Approval Period

1 year

References

2. Evidence-Based Medicine Analysis: "Non-Steroidal Antiandrogens/Androgen Biosynthesis Inhibitors", UMKC-DIC; October 2019.
6. USPDI, Micromedex; 2019.